Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

49.03USD
22 May 2015
Change (% chg)

$-0.31 (-0.63%)
Prev Close
$49.34
Open
$49.12
Day's High
$49.42
Day's Low
$48.91
Volume
923,949
Avg. Vol
1,416,142
52-wk High
$49.42
52-wk Low
$39.28

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company’s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products,... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $72,993.77
Shares Outstanding(Mil.): 1,488.76
Dividend: 0.24
Yield (%): 1.96

Financials

  ABT.N Industry Sector
P/E (TTM): 36.73 37.22 39.17
EPS (TTM): 1.33 -- --
ROI: 6.22 16.24 15.58
ROE: 8.95 16.99 16.57
Search Stocks

Fitch Downgrades Abbotts's L-T IDR to 'A'; Outlook Revised to Stable

(The following statement was released by the rating agency) CHICAGO, May 18 (Fitch) Fitch Ratings has downgraded Abbott Laboratories' (Abbott) long-term Issuer Default Rating (IDR) by one notch to 'A' and revised the Rating Outlook to Stable from Negative. In addition, the company's short-term IDR has been affirmed at 'F1'. Abbott had $8.9 billion in outstanding debt at March 31, 2015. A full list of Fitch's ratings actions follows at the end of this release. KEY RATING DRIVERS -- Fitch exp

18 May 2015

AstraZeneca digs into precision medicine with lung, heart deals

LONDON, May 13 - AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease.

12 May 2015

Mylan reports profit, maintains commitment to acquire Perrigo

May 5 - Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland-based Perrigo Co.

05 May 2015

Abbott says its payoff from Mylan deal surged

- Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

UPDATE 1-Abbott says its payoff from Mylan deal surged

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

CORRECTED-Abbott says payoff from Mylan deal surges, as Mylan shares leap

April 22 - Abbott Laboratories on Wednesday said its initial proceeds of $5.3 billion from the recent sale to Mylan of part of its generic drug business were now worth more than $7 billion because of appreciation of the stock it obtained in the deal.

22 Apr 2015

Abbott profit beats expectations, sales of branded generics jump

- Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

UPDATE 1-Abbott profit beats expectations, sales of branded generics jump

April 22 - Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

Abbott Labs profit from continuing operations more than doubles

April 22 - Abbott Laboratories' net earnings from continuing operations more than doubled in the first quarter, with strong performance in its branded generics, international nutrition and diagnostics divisions.

22 Apr 2015

Wall St. falls from records, led by technology stocks

NEW YORK - U.S. stocks finished down on Tuesday, a day after the S&P and Dow hit records, and the Nasdaq retreated with technology stocks.

03 Mar 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.35 -1.07
Pfizer Inc. (PFE.N) $34.28 -0.08
Novartis AG (NOVN.VX) CHF98.10 +0.05
Merck & Co., Inc. (MRK.N) $59.38 -0.72
Sanofi SA (SASY.PA) €91.11 -1.19
AstraZeneca plc (AZN.L) 4,473.50p +48.50
GlaxoSmithKline plc (GSK.L) 1,464.50p +14.00
Eli Lilly and Co (LLY.N) $74.30 +0.03
Amgen, Inc. (AMGN.OQ) $163.58 -0.26
Boston Scientific Corporation (BSX.N) $17.83 -0.04

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks